Denali Therapeutics Sees Q4 Sales $30.000M-$32.000M vs $22.659M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Denali Therapeutics (NASDAQ:DNLI) sees Q4 sales of $30.000 million-$32.000 million vs $22.659 million analyst estimate.
Denali Therapeutics (NASDAQ:DNLI) sees Q4 sales of $30.000 million-$32.000 million vs $22.659 million analyst estimate.